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The prevalence of psychotropic medication treatment for children and adolescents with emotional and behavioral disorders has significantly increased in the United States during the last few decades, particularly in the last 15 years.
Specifically, the 5 through 14-year-old age group has experienced a great increase in stimulant treatment for attention-deficit/hyperactivity disorder (ADHD), and the 15 through 19-year-old age group has had sizable increases in the use of antidepressant medications. 1-2 hpproved and unapproved indications for psychotropic medications in young children are not extensive. These include: short-term use of analgesics and sedatives/hypnotics for pain relief; hydroxyzine for situational anxiety associated with medical, presurgical, and dental procedures; tricyclic antidepressants for nocturnal enuresis (6-year-olds and older); and amphetamines for ADHD in those 3 years old and older. 3 Accordingly, the prevalence of psychotropic medication treatment for children younger than 5 years old has not received much professional attention until recently.
4-6
Concern about this age group relates to off-label (unlabeled) use, ie, for treatment indications with little or no proven efficacy and lacking product package insert labeling information approved by the US Food and Drug Administration (FDA). 7 One psychiatric newsletter, citing FDA-compiled marketing data, reported that 3000 prescriptions for fluoxetine hydrochloride were written for children aged younger than 1 year in 1994. 8 In a 1998 professional meeting report, 5 pediatric researchers noted that 57% of 223 Michigan Medicaid enrollees aged younger than 4 years with a diagnosis of ADHD received at least 1 psychotropic medication to treat this condition during a 15-month period in 1995-1996. Of the treatments, methylphenidate and clonidine were prescribed most often.
Although the use of psychotropic medication in preschool-aged children compared with older youths is relatively small, the reports cited argue for additional assessment to more systematically estimate its use. Consequently, 3 large, computerized data sources were used to estimate total, age-specific, and gender-specific psychotropic medication prevalence for 2 through 4-year-olds; to compare prevalence in the youngest age group with that in older children and adolescents; and to show utilization trends in the 5-year span from 1991-1995. Study Measures:tJ Psychotropic medication prevalence was defined for each study year as the frequency of persons with 1 or more HMO pharmacy records or Medicaid prescription claims for a psychotropic medication class, subclass, or specific medication per 1000 enrolled youths. Time trends were assessed across the 5-year span with data from 3 cross-sectional annual analyses (1991, 1993 , and 1995).
METHODSD
For age-specific prevalence, children were grouped into 4 age strata (aged 2-4, 5-9, 10-14, and 15-19 years) according to US census categories. Data analyses focused on children aged 2 through 4 years. We were unable to investigate psychotropic medication use in infants 1 year old or younger in the 2 Medicaid populations because year of birth is recorded in a 2-digit field. Thus, "95" could refer to someone born in 1895 or 1995. We were unable, therefore, to distinguish those 1 year old and younger from 100-and 101-year-olds. We do present data on methylphenidate use in A separate analysis was performed to examine medication use among preschool-aged children by year of age.
Gender-specific prevalence provided separate prevalence rates for boys and for girls. antidepressants), and neuroleptics. Selection was based on the frequent use of stimulants and antidepressants and the public health significance of the use of neuroleptics in the very young. In addition, 2 specific medications (methylphenidate and clonidine) were examined because their use alone or as a combined treatment has increased substantially since the early 1990s. All the drugs were identified using a data dictionary encompassing the national drug codes for each of the 3 study years. The study was given an exempt classification by the institutional review board-expedited review.
RESULTS
.1:J Total Psychotropic Medication Prevalence .1:J
The rank order of psychotropic medication prevalence in 1995 for the MWM program shows that, per 1000 enrollees, stimulants (12.3) were the leading treatment among those 2 through 4 years old, followed by antidepressants (3.2), clonidine (2.3), and neuroleptics (0.9) ( Table 1) . Within classes, methylphenidate prevalence (11.1 per 1000 enrollees)
represented 90% of the stimulant treatment, while TCA prevalence (2.4 per 1000 enrollees) led the antidepressant class.
A similar ranking of medication prevalence in 1995 was observed for the MAM program, while preschool-aged children in the HMO had nearly 3 times more clonidine use than antidepressant use (Table 1) . .. . between sites showed that trends were similar in all 3 sites, with minor deviations for neuroleptics and antidepressants in the population enrolled in the HMO (Table 1) . Specifically, the methylphenidate prevalence increase by site was:
of 10
MWM, 3-fold; MAM, 1.7-fold; and HMO, 3.1-fold. Increases were more dramatic when the base prevalence was low. For example, methylphenidate use in the HMO was the lowest of the 3 sites, but its rise from 1.3 per 1000 enrollees in 1991 to 4.0 per 1000 in 1995 represented the largest methylphenidate increase (3.1-fold) across the 3 sites (Table 1) COMMENT .!J Several prominent trends characterized the use of psychotropic medications in preschoolers during the early to mid 1990s. Overall, there were large increases for all study medications (except the neuroleptics) and considerable variation according to gender, age, geographic region, and health care system. These findings are remarkable in light of the limited knowledge base that underlies psychotropic medication use in very young children. 10 Controlled clinical studies to evaluate the efficacy and safety of psychotropic medications for preschoolers are rare. 3 Efficacy data are essentially lacking for clonidine and the SSRls and methylphenidate's adverse effects for preschool children are more pronounced than for older youths. 11 Consequently, the vast majority of psychotropic medications prescribed for preschoolers are being used off-label. 7 Specific study findings are discussed below according to 3 major outcomes: prevalence findings for specific medications; age-and gender-specific data; and geographic and health care system variations. The combined use of clonidine and methylphenidate has been associated with questions of safety 16, 21 and has been debated. 22 Unfortunately, the present data do not distinguish single vs concomitant medication use, information vital to understanding how these agents are being used in children. Such an analysis is better undertaken in a continuously enrolled cohort so that censored data do not create artifactual findings. We are currently conducting a continuously enrolled retrospective cohort study.
Prevalence FindingsS timulant treatment in preschoolers increased
Antidepressants were the second most commonly preSCribed psychotropic class of drugs for preschoolers, and their use increased substantially from 1991-1995. Tricyclic antidepressants still represent the bulk of early childhood antidepressant use, although the growth in use of SSRls was strong in those enrolled in both Medicaid programs but very modest in those in the HMO. The proportional decrease in use of TCAs was largely explained by the recent increase in use of SSRls, a trend we have previously shown for older youths 2 and one that has been documented in adults. 23 The use of TCAs for enuresis is common among 5 through 13-year-olds, 24 but its use in the preschool group is puzzling. It is also likely that some use of imipramine and desipramine was related to the treatment of ADHD in preschoolers. 25
Neuroleptic use was infrequent and relatively stable across the study period. The neuroleptic prevalence rate in this preschool data showed rates one-tenth to one-half the annual prevalence among 5 through 19-year-olds in Rome from 1986 through 1991. 26 Both the neuroleptic and antidepressant findings bring new information on population-based prevalence and provide some benchmarks to chart the use of these agents in ambulatory settings. Additional clinical interpretation, however, awaits prospective outcome studies.
Age-and Gender-Specific Prevalence Findings .!l Preschoolers' use of methylphenidate showed increases similar to those of 5 through 14-year-olds, suggesting that the expanded use of this medication for attentional disorders in US youths extends even to the very young. It is notable that the largest gains in use occurred among high school-aged students (15 through 19-year-olds), a trend that has been documented from county school survey data. 13
Geographic and Health Care System VariationsD isparities in psychotropic medication prevalence data between the 2 state Medicaid program populations are provocative and suggest numerous hypotheses. These include differences between the states in (1) policies for eligibility or access to continuing care; (2) the proportion of individuals with emotional or mental disorders that may be related to the proportion of youths receiving Supplemental Security Income and foster care in each state; (3) preschool health assessment and referral programs; (4) physician specialty training, particularly among psychiatrists and primary care providers, with resultant referral or practice differences; (5) the cultural values that underlie families' decisions to accept or reject medication for behavioral or mental disorders; and (6) racial/ethnic population differences that may affect cultural orientations and beliefs. Also notable is the finding that the HMO prevalence rates, collectively, were substantially lower than those of the Medicaid programs. In this instance, geography and clinical population factors confound the prevalence findings related to HMO vs Medicaid systems. The presence of less severely disabled youths in the HMO population is likely to explain a large part of the differences, but geographic and patient cultural factors need to be considered as well. Also, the rapid expansion of Supplemental Security Income benefits since 1990 resulted in more youths with ADHD being eligible for Medicaid coverage than in previous years. Z7 LimitationsT he study is limited in several ways. First, the findings may be generalizable to comparable Medicaid programs and to group-model HMO enrollees, but the extent to which they may apply to other treatment settings is unknown. Second, the cross-sectional nature of the data from the 3 study years do not permit a follow-up of the natural course of treatment. Until a continuously enrolled cohort is assembled, descriptive data on the natural course of treatment and prescription changes over time cannot be adequately assessed. However, noncontinuously enrolled individuals make up the bulk of the Medicaid membership. Thus, capturing these annual data snapshots of both noncontinuous and continuous enrollees is useful for clinical description. Third, no diagnostic codes were linked to the medications in this analysis, thus limiting information about why certain medications were selected. Fourth, computerized data sources use a limited number of variables to describe the clinical patterns in the usual practice settings. However, they have the advantage of describing the usual practice setting without the artificiality and the interference that prospective studies impose on physicians' decisions about medication and patients' decisions about treatment. Compared with data from specialty clinic samples, data from community treatment settings provide a far more accurate assessment of medication practices, therapy variations, and treatment. Adding outcome assessments would allow the effectiveness of the treatments to be evaluated.
Clinical Research Recommendations 'B
ecause children's responses to medications are not necessarily similar to those of adults, systematic and careful outcome research specifically needs to be done for them. 7 Two types of studies would help provide more systematic information on psychotropic drug therapy in children. First, epidemiologic (naturalistic) studies could describe youth treatment in major medical settings (eg, traditional preferred provider organizations, Medicaid, salaried medical group-model HMOs, and other managed care organizations) to document types of treatments, diagnosis, severity, and time in treatment and to evaluate clinical outcomes. Outcome measures could include symptom control; social, day care, and preschool functioning; parent satisfaction; reasons for initiation and discontinuation; and adverse drug events. 28 Second, randomized, double-blind, controlled clinical trials are needed for off-label indications to evaluate dosages, efficacy, and safety of single and multiple agents shown to be commonly used or widely recommended. For disorders that occur very infrequently or questionable combinations of drug therapy with unknown risks, a case registry approach may be useful.
Future studies using large databases for clinical descriptive information should require that the year of birth be stored as a 4-digit number to avoid misclassification of elders as youths, Finally, youths in Medicaid programs should be subdivided by type of eligibility (eg, low income [formerly Aid to Families with Dependent Children, now called Temporary Assistance for Needy Families], Supplemental Security Income, or foster care) so that the total treatment' prevalence, which includes children with known disabilities and major social stressors, will not be unfairly compared with that of less impaired youths in non-Medicaid populations. 27
Unresolved questions involve the long-term safety of psychotropic medications, particularly in light of earlier ages of initiation and longer durations of treatment. While it is reassuring that anecdotal reports have rarely documented these problems, the possibility of adverse effects on the developing brain cannot be ruled out. 29 Active surveillance mechanisms for ascertaining subtle changes that the developing personality may undergo as a result of a psychotropic drug's impact on brain neurotransmitters should be developed. 
